Literature DB >> 26528545

Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling.

Ikuo Nakamura, Kais Zakharia, Bubu A Banini, Dalia S Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D Moser, Hassan M Shaleh, Sarah R Thornburgh, Ian Walters, Lewis R Roberts.   

Abstract

Entities:  

Year:  2015        PMID： 26528545      PMCID： PMC4631495          DOI： 10.1371/journal.pone.0142355

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


× No keyword cloud information.
The following information is missing from the Funding section: This research was supported by a National Institutes of Health (NIH) grant, 3R01CA165076-03S2, Research Supplement to Promote Diversity in Health-Related Research, to Hassan M. Shaleh.
  1 in total

1.  Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.

Authors:  Ikuo Nakamura; Kais Zakharia; Bubu A Banini; Dalia S Mikhail; Tae Hyo Kim; Ju Dong Yang; Catherine D Moser; Hassan M Shaleh; Sarah R Thornburgh; Ian Walters; Lewis R Roberts
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240
  1 in total
  1 in total

Review 1.  Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Authors:  Jing-Si Wang; Qiu-Yun Zhang; Jin-Lian Cheng; Lan-Yu Chen; Nai-Li Yao; Gui-Zhi Sun; Yu-Ling Chu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.